Dover has entered right into a definitive agreement to amass Malema Engineering Corp, a US designer and producer of high-precision, mission-critical flow-measurement and management instruments for the biopharmaceutical, semiconductor and industrial sectors.
Malema’s products will increase Dover’s biopharma single-use production providing, which already contains Quattroflow pumps, CPC connectors, and em-tec flowmeters.
Based in Boca Raton, Florida, and with services in San Jose, California, Singapore, South Korea and India, Malema expects to generate roughly US$40 million–45 million in income during the full year 2022.
When เครื่องมือตรวจวัดความดันเลือดเรียกว่า closes, Malema will become part of the PSG business unit within Dover’s Pumps & Process Solutions segment.
“We see a tremendous long-term growth alternative in the bioprocessing trade driven by a strong and rising pipeline of efficient novel biologic medication, biosimilars, protein therapies, non-COVID mRNA vaccines, as nicely as budding cell & gene therapies,” says PSG’s president Karl Buscher. “Additionally, the rising adoption of extra environment friendly single-use production processes supports a strong outlook for our offerings of single-use parts to end-customers. We imagine that pairing Malema’s technology with our existing portfolio of single-use pumps for biopharma processing will greatly enhance the accuracy and value proposition of our options to our clients.”
“We are methodically building out our biopharma platform via proactive capacity additions, new product development, and opportunistic acquisitions of highly-attractive area of interest component applied sciences,” stated Richard Tobin, president and CEO of Dover. “Malema represents a strategic and highly-complementary flow-control and sensing know-how and further strengthens our sensor portfolio with new proprietary know-how. In addition to attractive biopharma functions, we expect strong growth in the semiconductor house on the capability growth and re-shoring tailwinds.”
Share

Leave a Reply